TY  - JOUR
AU  - Dramićanin, Tatjana
AU  - Dramićanin, Miroslav
AU  - Jokanović, Vukoman R.
AU  - Nikolić-Vukosavljević, Dragica
AU  - Dimitrijević, Bogomir B.
PY  - 2005
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2954
AB  - Specimens of malignant and normal female human breast tissues were analyzed after surgery by means of synchronous luminescence spectroscopy. Measurements were performed in the ranges of excitation wavelengths from 330 to 650 nm and synchronous wavelengths from 30 to 120 nm to obtain ordinary and first derivative three-dimensional total synchronous luminescence spectra (3d-TSLS) of each specimen. Arithmetic mean of these spectra has been calculated for normal and malignant specimens and analyzed to establish criteria for tissue differentiation. Spectral domain volumes (volumes below luminescence intensity surface) and mean spectral slopes have been calculated and also analyzed as tissue discrimination criteria. The obtained results are discussed in view of the possible relevance of synchronous luminescence spectroscopy in discrimination between normal and malignant breast tissue.
T2  - Photochemistry and Photobiology
T1  - Three-dimensional total synchronous luminescence spectroscopy criteria for discrimination between normal and malignant breast tissues
VL  - 81
IS  - 6
SP  - 1554
EP  - 1558
DO  - 10.1562/2005-02-15-RA-442
ER  - 

@article{
author = "Dramićanin, Tatjana and Dramićanin, Miroslav and Jokanović, Vukoman R. and Nikolić-Vukosavljević, Dragica and Dimitrijević, Bogomir B.",
year = "2005",
abstract = "Specimens of malignant and normal female human breast tissues were analyzed after surgery by means of synchronous luminescence spectroscopy. Measurements were performed in the ranges of excitation wavelengths from 330 to 650 nm and synchronous wavelengths from 30 to 120 nm to obtain ordinary and first derivative three-dimensional total synchronous luminescence spectra (3d-TSLS) of each specimen. Arithmetic mean of these spectra has been calculated for normal and malignant specimens and analyzed to establish criteria for tissue differentiation. Spectral domain volumes (volumes below luminescence intensity surface) and mean spectral slopes have been calculated and also analyzed as tissue discrimination criteria. The obtained results are discussed in view of the possible relevance of synchronous luminescence spectroscopy in discrimination between normal and malignant breast tissue.",
journal = "Photochemistry and Photobiology",
title = "Three-dimensional total synchronous luminescence spectroscopy criteria for discrimination between normal and malignant breast tissues",
volume = "81",
number = "6",
pages = "1554-1558",
doi = "10.1562/2005-02-15-RA-442"
}

Dramićanin, T., Dramićanin, M., Jokanović, V. R., Nikolić-Vukosavljević, D.,& Dimitrijević, B. B.. (2005). Three-dimensional total synchronous luminescence spectroscopy criteria for discrimination between normal and malignant breast tissues. in Photochemistry and Photobiology, 81(6), 1554-1558.
https://doi.org/10.1562/2005-02-15-RA-442

Dramićanin T, Dramićanin M, Jokanović VR, Nikolić-Vukosavljević D, Dimitrijević BB. Three-dimensional total synchronous luminescence spectroscopy criteria for discrimination between normal and malignant breast tissues. in Photochemistry and Photobiology. 2005;81(6):1554-1558.
doi:10.1562/2005-02-15-RA-442 .

Dramićanin, Tatjana, Dramićanin, Miroslav, Jokanović, Vukoman R., Nikolić-Vukosavljević, Dragica, Dimitrijević, Bogomir B., "Three-dimensional total synchronous luminescence spectroscopy criteria for discrimination between normal and malignant breast tissues" in Photochemistry and Photobiology, 81, no. 6 (2005):1554-1558,
https://doi.org/10.1562/2005-02-15-RA-442 . .

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Demajo, Miroslav
AU  - Todorović-Raković, N
AU  - Nikolić-Vukosavljević, Dragica
AU  - Nešković-Konstantinović, Zora
AU  - Krtolica-Žikić, Koviljka
AU  - Veljković, Veljko
AU  - Prljić, Jelena
AU  - Dimitrijević, Bogomir B.
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2769
AB  - Although overexpression of TGF-beta(1) protein has been demonstrated in advanced breast cancer(BC) patients, as well as in other solid tumours, the molecular mechanism of this process remains obscure. This paper proposes that a genetic/epigenetic alteration might occur in the TGF-beta(1) gene, within the region coding for the recognition site with TGF(beta) receptor type II, leading to a disruption of the ligand-receptor interaction and triggering the TGF-beta(1) cascade-related BC progression. To establish the operational framework for this hypothesis, in the present study, this recognition site was identified by the Informational Spectrum Method (ISM) to comprise two TGF-beta(1) peptides (positions 47-66 as and 83-112 aa) and one receptor peptide at positions 112-151 as of the extracellular domain of the receptor (TbetaRII(M)). The TbetaRII(M) locus was further evaluated by ISM-derived deletion analysis of the TbetaRII sequences. To provide experimental support for the proposed model, a pilot study of plasma TGF-beta(1) analysis was performed in advanced BC patients (n = 8). Two commercial ELISA assays, one with specific alphaTGF-beta(1) MAb (MAb) and other with TbetaRII(M) as the immobilized phase, revealed pronounced differences in the pattern of plasma TGF-beta(1) elevation. In MAb-profile, the TGF-beta(1) increase was detected in 7 of 8 patients, whereas analogous TbetaRII(M)-profile revealed the elevation in 3 of 8 patients, taking a 50% of maximal elevation as the cut-off value. These findings are consistent with the proposed aberration of TGF-beta(1) ligand within the TbetaRII recognition site. Summarizing, this model system is a good starting point for further genetic studies, particularly on genetic/epigenetic alterations of sequences involved in TGF-beta(1) and TbetaRII(M) interaction, with putative prognostic value for breast cancer. (C) 2004 Elsevier Ltd. All rights reserved.
T2  - Medical Hypotheses
T1  - Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer
VL  - 62
IS  - 5
SP  - 727
EP  - 732
DO  - 10.1016/j.mehy.2003.11.027
ER  - 

@article{
author = "Ivanović, Vesna and Demajo, Miroslav and Todorović-Raković, N and Nikolić-Vukosavljević, Dragica and Nešković-Konstantinović, Zora and Krtolica-Žikić, Koviljka and Veljković, Veljko and Prljić, Jelena and Dimitrijević, Bogomir B.",
year = "2004",
abstract = "Although overexpression of TGF-beta(1) protein has been demonstrated in advanced breast cancer(BC) patients, as well as in other solid tumours, the molecular mechanism of this process remains obscure. This paper proposes that a genetic/epigenetic alteration might occur in the TGF-beta(1) gene, within the region coding for the recognition site with TGF(beta) receptor type II, leading to a disruption of the ligand-receptor interaction and triggering the TGF-beta(1) cascade-related BC progression. To establish the operational framework for this hypothesis, in the present study, this recognition site was identified by the Informational Spectrum Method (ISM) to comprise two TGF-beta(1) peptides (positions 47-66 as and 83-112 aa) and one receptor peptide at positions 112-151 as of the extracellular domain of the receptor (TbetaRII(M)). The TbetaRII(M) locus was further evaluated by ISM-derived deletion analysis of the TbetaRII sequences. To provide experimental support for the proposed model, a pilot study of plasma TGF-beta(1) analysis was performed in advanced BC patients (n = 8). Two commercial ELISA assays, one with specific alphaTGF-beta(1) MAb (MAb) and other with TbetaRII(M) as the immobilized phase, revealed pronounced differences in the pattern of plasma TGF-beta(1) elevation. In MAb-profile, the TGF-beta(1) increase was detected in 7 of 8 patients, whereas analogous TbetaRII(M)-profile revealed the elevation in 3 of 8 patients, taking a 50% of maximal elevation as the cut-off value. These findings are consistent with the proposed aberration of TGF-beta(1) ligand within the TbetaRII recognition site. Summarizing, this model system is a good starting point for further genetic studies, particularly on genetic/epigenetic alterations of sequences involved in TGF-beta(1) and TbetaRII(M) interaction, with putative prognostic value for breast cancer. (C) 2004 Elsevier Ltd. All rights reserved.",
journal = "Medical Hypotheses",
title = "Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer",
volume = "62",
number = "5",
pages = "727-732",
doi = "10.1016/j.mehy.2003.11.027"
}

Ivanović, V., Demajo, M., Todorović-Raković, N., Nikolić-Vukosavljević, D., Nešković-Konstantinović, Z., Krtolica-Žikić, K., Veljković, V., Prljić, J.,& Dimitrijević, B. B.. (2004). Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer. in Medical Hypotheses, 62(5), 727-732.
https://doi.org/10.1016/j.mehy.2003.11.027

Ivanović V, Demajo M, Todorović-Raković N, Nikolić-Vukosavljević D, Nešković-Konstantinović Z, Krtolica-Žikić K, Veljković V, Prljić J, Dimitrijević BB. Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer. in Medical Hypotheses. 2004;62(5):727-732.
doi:10.1016/j.mehy.2003.11.027 .

Ivanović, Vesna, Demajo, Miroslav, Todorović-Raković, N, Nikolić-Vukosavljević, Dragica, Nešković-Konstantinović, Zora, Krtolica-Žikić, Koviljka, Veljković, Veljko, Prljić, Jelena, Dimitrijević, Bogomir B., "Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer" in Medical Hypotheses, 62, no. 5 (2004):727-732,
https://doi.org/10.1016/j.mehy.2003.11.027 . .

TY  - JOUR
AU  - Nikolić-Vukosavljević, Dragica
AU  - Todorović-Raković, N
AU  - Demajo, Miroslav
AU  - Ivanović, Vesna
AU  - Neskovic, B
AU  - Markicevic, M
AU  - Nešković-Konstantinović, Zora
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2869
AB  - A pilot study was conducted to assess whether plasma levels of transforming growth factor-beta 1 (TGF-beta 1) might facilitate biological subgrouping of postmenopausal metastatic breast cancer patients, and, accordingly, its applicability in clinical oncology. This study included 29 postmenopausal metastatic breast cancer patients. Plasma TGF-beta 1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Estrogen and progesterone receptors were assayed by radioligand binding, in accordance with the recommendation of the EORTC. Concentrations of 17-beta estradiol were determined by using ELISA-microwell method (DIALAB). Overall survival was followed for 24 months for each individual patient. Stratification of the patients by ER/PR status showed that 14 patients with estrogen receptor-negative, progesterone receptor-negative carcinomas displayed a statistically significant increase in plasma TGF-beta 1 levels when compared to plasma TGF-beta 1 levels of 6 patients with ER-positive, PR-positive carcinomas (P=0.04). In this study, 7 out of 14 patients with negative receptors status had no plasma TGF-beta 1 values overlapping with patients having positive receptors status. The TGF-beta 1 cut-off value was defined as the highest plasma TGF-beta 1 level of ER-positive, PR-positive patients: 3.28 ng/ml. This plasma TGF-beta 1 cut-off value defined low-risk subgroup of 19 patients (! 3.28 ng/ml) and high-risk subgroup of 10 patients ( GT 3.28 ng/ml) (P=0.047). Plasma TGF-beta 1-related survival was independent of the classical prognostic factors of metastatic breast cancer. Accordingly, a clinical significance of elevated plasma TGF-beta 1 levels may be suggested.
T2  - Clinical and Experimental Metastasis
T1  - Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients
VL  - 21
IS  - 7
SP  - 581
EP  - 585
UR  - https://hdl.handle.net/21.15107/rcub_vinar_2869
ER  - 

@article{
author = "Nikolić-Vukosavljević, Dragica and Todorović-Raković, N and Demajo, Miroslav and Ivanović, Vesna and Neskovic, B and Markicevic, M and Nešković-Konstantinović, Zora",
year = "2004",
abstract = "A pilot study was conducted to assess whether plasma levels of transforming growth factor-beta 1 (TGF-beta 1) might facilitate biological subgrouping of postmenopausal metastatic breast cancer patients, and, accordingly, its applicability in clinical oncology. This study included 29 postmenopausal metastatic breast cancer patients. Plasma TGF-beta 1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Estrogen and progesterone receptors were assayed by radioligand binding, in accordance with the recommendation of the EORTC. Concentrations of 17-beta estradiol were determined by using ELISA-microwell method (DIALAB). Overall survival was followed for 24 months for each individual patient. Stratification of the patients by ER/PR status showed that 14 patients with estrogen receptor-negative, progesterone receptor-negative carcinomas displayed a statistically significant increase in plasma TGF-beta 1 levels when compared to plasma TGF-beta 1 levels of 6 patients with ER-positive, PR-positive carcinomas (P=0.04). In this study, 7 out of 14 patients with negative receptors status had no plasma TGF-beta 1 values overlapping with patients having positive receptors status. The TGF-beta 1 cut-off value was defined as the highest plasma TGF-beta 1 level of ER-positive, PR-positive patients: 3.28 ng/ml. This plasma TGF-beta 1 cut-off value defined low-risk subgroup of 19 patients (! 3.28 ng/ml) and high-risk subgroup of 10 patients ( GT 3.28 ng/ml) (P=0.047). Plasma TGF-beta 1-related survival was independent of the classical prognostic factors of metastatic breast cancer. Accordingly, a clinical significance of elevated plasma TGF-beta 1 levels may be suggested.",
journal = "Clinical and Experimental Metastasis",
title = "Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients",
volume = "21",
number = "7",
pages = "581-585",
url = "https://hdl.handle.net/21.15107/rcub_vinar_2869"
}

Nikolić-Vukosavljević, D., Todorović-Raković, N., Demajo, M., Ivanović, V., Neskovic, B., Markicevic, M.,& Nešković-Konstantinović, Z.. (2004). Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients. in Clinical and Experimental Metastasis, 21(7), 581-585.
https://hdl.handle.net/21.15107/rcub_vinar_2869

Nikolić-Vukosavljević D, Todorović-Raković N, Demajo M, Ivanović V, Neskovic B, Markicevic M, Nešković-Konstantinović Z. Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients. in Clinical and Experimental Metastasis. 2004;21(7):581-585.
https://hdl.handle.net/21.15107/rcub_vinar_2869 .

Nikolić-Vukosavljević, Dragica, Todorović-Raković, N, Demajo, Miroslav, Ivanović, Vesna, Neskovic, B, Markicevic, M, Nešković-Konstantinović, Zora, "Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients" in Clinical and Experimental Metastasis, 21, no. 7 (2004):581-585,
https://hdl.handle.net/21.15107/rcub_vinar_2869 .

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Todorović-Raković, N
AU  - Demajo, Miroslav
AU  - Nešković-Konstantinović, Zora
AU  - Subota, Vesna
AU  - Ivanišević-Milovanović, Olivera
AU  - Nikolić-Vukosavljević, Dragica
PY  - 2003
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2617
AB  - We examined the association between an elevated plasma TGF-beta(1) level and the disease progression of advanced breast cancer (BC) patients (n = 44). TGF-beta(1) levels were detected by an enzyme-linked immunosorbent assay (ELISA). Platelet carryover and in vitro platelet activation in our plasma samples was assessed and found to be insignificant. Plasma TGF-beta(1) values were significantly elevated (P LT 0.05) in stage IIIB/IV patients (median value: 2.40 ng/ml, range: 0.13-8.48 ng/ml, n=44) compared with healthy donors (median value: 1.30 ng/ml, range: 0.41-4.93 ng/ml, n=36). Although pronounced in metastatic patients, especially those who had been newly diagnosed, TGF- and beta;(1) elevation was independent of tumour mass, site of distant metastases, histopathological type, steroid receptor (SR) content and age of the BC patients. Follow-up of 6 patients indicated a relationship between the plasma TGF- and beta;(1) and the patients response. This suggests that TGF- and beta;(1), may be a promising prognostic marker for breast cancer patients with advanced disease. Confirmatory large-scale studies are needed, particularly given the overlap of values between our different subgroups analysed.
T2  - European Journal of Cancer
T1  - Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression
VL  - 39
IS  - 4
SP  - 454
EP  - 461
DO  - 10.1016/S0959-8049(02)00502-6
ER  - 

@article{
author = "Ivanović, Vesna and Todorović-Raković, N and Demajo, Miroslav and Nešković-Konstantinović, Zora and Subota, Vesna and Ivanišević-Milovanović, Olivera and Nikolić-Vukosavljević, Dragica",
year = "2003",
abstract = "We examined the association between an elevated plasma TGF-beta(1) level and the disease progression of advanced breast cancer (BC) patients (n = 44). TGF-beta(1) levels were detected by an enzyme-linked immunosorbent assay (ELISA). Platelet carryover and in vitro platelet activation in our plasma samples was assessed and found to be insignificant. Plasma TGF-beta(1) values were significantly elevated (P LT 0.05) in stage IIIB/IV patients (median value: 2.40 ng/ml, range: 0.13-8.48 ng/ml, n=44) compared with healthy donors (median value: 1.30 ng/ml, range: 0.41-4.93 ng/ml, n=36). Although pronounced in metastatic patients, especially those who had been newly diagnosed, TGF- and beta;(1) elevation was independent of tumour mass, site of distant metastases, histopathological type, steroid receptor (SR) content and age of the BC patients. Follow-up of 6 patients indicated a relationship between the plasma TGF- and beta;(1) and the patients response. This suggests that TGF- and beta;(1), may be a promising prognostic marker for breast cancer patients with advanced disease. Confirmatory large-scale studies are needed, particularly given the overlap of values between our different subgroups analysed.",
journal = "European Journal of Cancer",
title = "Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression",
volume = "39",
number = "4",
pages = "454-461",
doi = "10.1016/S0959-8049(02)00502-6"
}

Ivanović, V., Todorović-Raković, N., Demajo, M., Nešković-Konstantinović, Z., Subota, V., Ivanišević-Milovanović, O.,& Nikolić-Vukosavljević, D.. (2003). Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression. in European Journal of Cancer, 39(4), 454-461.
https://doi.org/10.1016/S0959-8049(02)00502-6

Ivanović V, Todorović-Raković N, Demajo M, Nešković-Konstantinović Z, Subota V, Ivanišević-Milovanović O, Nikolić-Vukosavljević D. Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression. in European Journal of Cancer. 2003;39(4):454-461.
doi:10.1016/S0959-8049(02)00502-6 .

Ivanović, Vesna, Todorović-Raković, N, Demajo, Miroslav, Nešković-Konstantinović, Zora, Subota, Vesna, Ivanišević-Milovanović, Olivera, Nikolić-Vukosavljević, Dragica, "Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression" in European Journal of Cancer, 39, no. 4 (2003):454-461,
https://doi.org/10.1016/S0959-8049(02)00502-6 . .

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Todorović-Raković, N
AU  - Demajo, Miroslav
AU  - Nešković-Konstantinović, Zora
AU  - Nikolić-Vukosavljević, Dragica
AU  - Ivanišević-Milovanović, Olivera
AU  - Mitrovic, L
PY  - 2001
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2438
AB  - There has been much controversy concerning the detection of plasma TGF-beta (1) levels in breast cancer patients. The present study provides preliminary evidence on underestimated plasma TGF-beta (1) levels due to ex vivo proteolysis and previous therapeutic treatment of breast cancer patients, as detected by a commercial ELISA immunoassay. Our results revealed that the addition of protease inhibitors: phenylmethylsulfonyl fluoride and aprotinin, to the plasma preparation of healthy volunteers, has increased TGF-beta (1) median Value from 3.1 ng/mL to 33.9 ng/mL. Relative to that, in protease-inhibited plasma of locally advanced/metastatic breast cancer patients, significantly elevated TGF-beta (1) was observed (median value: 65.5 ng/mL), which included untreated and previously treated patients with median values of: 74.2 ng/mL and 58.1 ng/mL, respectively. These findings indicate to the potential usefulness of this plasma marker in breast cancer prognosis, thus deserving future clinical attention.
T2  - Jugoslovenska Medicinska Biohemija
T1  - Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients
VL  - 20
IS  - 2
SP  - 81
EP  - 87
UR  - https://hdl.handle.net/21.15107/rcub_vinar_2438
ER  - 

@article{
author = "Ivanović, Vesna and Todorović-Raković, N and Demajo, Miroslav and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica and Ivanišević-Milovanović, Olivera and Mitrovic, L",
year = "2001",
abstract = "There has been much controversy concerning the detection of plasma TGF-beta (1) levels in breast cancer patients. The present study provides preliminary evidence on underestimated plasma TGF-beta (1) levels due to ex vivo proteolysis and previous therapeutic treatment of breast cancer patients, as detected by a commercial ELISA immunoassay. Our results revealed that the addition of protease inhibitors: phenylmethylsulfonyl fluoride and aprotinin, to the plasma preparation of healthy volunteers, has increased TGF-beta (1) median Value from 3.1 ng/mL to 33.9 ng/mL. Relative to that, in protease-inhibited plasma of locally advanced/metastatic breast cancer patients, significantly elevated TGF-beta (1) was observed (median value: 65.5 ng/mL), which included untreated and previously treated patients with median values of: 74.2 ng/mL and 58.1 ng/mL, respectively. These findings indicate to the potential usefulness of this plasma marker in breast cancer prognosis, thus deserving future clinical attention.",
journal = "Jugoslovenska Medicinska Biohemija",
title = "Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients",
volume = "20",
number = "2",
pages = "81-87",
url = "https://hdl.handle.net/21.15107/rcub_vinar_2438"
}

Ivanović, V., Todorović-Raković, N., Demajo, M., Nešković-Konstantinović, Z., Nikolić-Vukosavljević, D., Ivanišević-Milovanović, O.,& Mitrovic, L.. (2001). Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients. in Jugoslovenska Medicinska Biohemija, 20(2), 81-87.
https://hdl.handle.net/21.15107/rcub_vinar_2438

Ivanović V, Todorović-Raković N, Demajo M, Nešković-Konstantinović Z, Nikolić-Vukosavljević D, Ivanišević-Milovanović O, Mitrovic L. Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients. in Jugoslovenska Medicinska Biohemija. 2001;20(2):81-87.
https://hdl.handle.net/21.15107/rcub_vinar_2438 .

Ivanović, Vesna, Todorović-Raković, N, Demajo, Miroslav, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, Ivanišević-Milovanović, Olivera, Mitrovic, L, "Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients" in Jugoslovenska Medicinska Biohemija, 20, no. 2 (2001):81-87,
https://hdl.handle.net/21.15107/rcub_vinar_2438 .